Current and emerging therapeutic options in adrenocortical cancer treatment

Journal of Oncology

Volumn , Issue , 2012, Pages

  Stigliano, Antonio ^a,b   Cerquetti, Lidia ^a,b   Sampaoli, Camilla ^a,b   Bucci, Barbara ^a,b   Toscano, Vincenzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,1 (2,4' DICHLORODIPHENYL) 2,2 DICHLOROETHANE; 1,1 (2,4' DICHLORODIPHENYL)ACETIC ACID; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CIXUTUMUMAB; DOXORUBICIN; DRUG METABOLITE; ETOPOSIDE; EVEROLIMUS; FIGITUMUMAB; FLUOROURACIL; GEFITINIB; GLYCOPROTEIN P; HYDROCORTISONE; IMATINIB; ISO 906; LINSITINIB; MITOTANE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SOMATOMEDIN C; SORAFENIB; STREPTOZOCIN; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX INSUFFICIENCY; ADRENALECTOMY; ANOREXIA; ANTIANGIOGENIC THERAPY; ATAXIA; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHEMORADIOTHERAPY; CLINICAL FEATURE; CYTOREDUCTIVE SURGERY; DEPRESSION; DIARRHEA; DISEASE FREE SURVIVAL; DROWSINESS; DRUG ACCUMULATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENDOCRINE SURGERY; HUMAN; LAPAROTOMY; LETHARGY; LIFE EXPECTANCY; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; METABOLIC ACTIVATION; MOLECULARLY TARGETED THERAPY; NAUSEA; NONHUMAN; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; RECURRENCE RISK; REVIEW; SURGICAL APPROACH; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERTIGO; VOMITING;

EID: 84866254100     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/408131     Document Type: Review

References (135)

1. National Cancer Institute, Third national cancer survey: incidental data. DHEW publication no. (NIH) 75787. NCI Monogr 41, 1975
2. Dackiw A. P. B., Lee J. E., Gagel R. F., Evans D. B., Adrenal cortical carcinoma. World Journal of Surgery 2001 25 7 914 926 2-s2.0-0034915765 10.1007/s00268-001-0030-7 (Pubitemid 32666394)
3. Bielinska M., Parviainen H., Kiiveri S., Heikinheimo M., Wilson D. B., Review paper: origin and molecular pathology of adrenocortical neoplasms. Veterinary Pathology 2009 46 2 194 210 2-s2.0-67650870201
4. Patalano A., Brancato V., Mantero F., Adrenocortical cancer treatment. Hormone Research 2009 71 1 99 104 2-s2.0-58549084169 10.1159/000178049
5. Gicquel C., Bertagna X., Le Bouc Y., Recent advances in the pathogenesis of adrenocortical tumours. European Journal of Endocrinology 1995 133 2 133 144 2-s2.0-0029115129
6. Gicquel C., Bertagna X., Gaston V., Coste J., Louvel A., Baudin E., Bertherat J., Chapuis Y., Duclos J. M., Schlumberger M., Plouin P. F., Luton J. P., Le Bouc Y., Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Research 2001 61 18 6762 6767 2-s2.0-0035884186 (Pubitemid 32896498)
7. Bläker H., Sutter C., Kadmon M., Otto H. F., Von Knebel-Doeberitz M., Gebert J., Helmke B. M., Analysis of somatic APC mutations in rare extracolonic tumors of patients with familial adenomatous polyposis coli. Genes Chromosomes and Cancer 2004 41 2 93 98 2-s2.0-4143091407 10.1002/gcc.20071 (Pubitemid 39096734)
8. Tissier F., Cavard C., Groussin L., Perlemoine K., Fumey G., Hagneré A. M., René-Corail F., Jullian E., Gicquel C., Bertagna X., Vacher-Lavenu M. C., Perret C., Bertherat J., Mutations of β -catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Research 2005 65 17 7622 7627 2-s2.0-24744454197 10.1158/0008-5472.CAN-05-0593 (Pubitemid 41297234)
9. Caron de Fromentel C., Soussi T., TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes and Cancer 1992 4 1 1 15 2-s2.0-0026579237
10. Hisada M., Garber J. E., Fung C. Y., Fraumeni J. F., Li F. P., Multiple primary cancers in families with Li-Fraumeni syndrome. Journal of the National Cancer Institute 1998 90 8 606 611 2-s2.0-0032522623 (Pubitemid 28204804)
11. Yano T., Linehan M., Anglard P., Lerman M. I., Daniel L. N., Stein C. A., Robertson C. N., LaRocca R., Zbar B., Genetic changes in human adrenocortical carcinomas. Journal of the National Cancer Institute 1989 81 7 518 523 2-s2.0-0024558302 (Pubitemid 19102220)
12. Beuschlein F., Reincke M., Karl M., Travis W. D., Jaursch-Hancke C., Abdelhamid S., Chrousos G. P., Allolio B., Clonal composition of human adrenocortical neoplasms. Cancer Research 1994 54 18 4927 4932 2-s2.0-0027967028 (Pubitemid 24289423)
13. Blake M. A., Slattery J. M. A., Kalra M. K., Halpern E. F., Fischman A. J., Mueller P. R., Boland G. W., Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancyinitial experience. Radiology 2006 238 3 970 977 2-s2.0-33344455256 10.1148/radiol.2383042164 (Pubitemid 43289929)
14. Ilias I., Sahdev A., Reznek R. H., Grossman A. B., Pacak K., The optimal imaging of adrenal tumours: a comparison of different methods. Endocrine-Related Cancer 2007 14 3 587 599 2-s2.0-35948992319 10.1677/ERC-07-0045 (Pubitemid 350074049)
15. Fassnacht M., Kenn W., Allolio B., Adrenal tumors: how to establish malignancy? Journal of Endocrinological Investigation 2004 27 4 387 399 2-s2.0-2942532589 (Pubitemid 38744621)
16. Seccia T. M., Fassina A., Nussdorfer G. G., Pessina A. C., Rossi G. P., Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocrine-Related Cancer 2005 12 1 149 159 2-s2.0-16444385246 10.1677/erc.1.00867 (Pubitemid 40477095)
17. Fassnacht M., Allolio B., Clinical management of adrenocortical carcinoma. Best Practice and Research 2009 23 2 273 289 2-s2.0-66149163113 10.1016/j.beem.2008.10.008
18. Assié G., Antoni G., Tissier F., Caillou B., Abiven G., Gicquel C., Leboulleux S., Travagli J. P., Dromain C., Bertagna X., Bertherat J., Schlumberger M., Baudin E., Prognostic parameters of metastatic adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2007 92 1 148 154 2-s2.0-33846089053 10.1210/jc.2006-0706 (Pubitemid 46067523)
19. Stojadinovic A., Ghossein R. A., Hoos A., Nissan A., Marshall D., Dudas M., Cordon-Cardo C., Jaques D. P., Brennan M. F., Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. Journal of Clinical Oncology 2002 20 4 941 950 2-s2.0-0037083656 10.1200/JCO.20.4.941 (Pubitemid 34141836)
20. Macfarlane D. A., Cancer of the adrenal cortex. The natural history, prognosis and treatment in a study of fifty-five cases. Annals of the Royal College of Surgeons of England 1958 23 3 155 186 2-s2.0-0001612824
21. Sullivan M., Boileau M., Hodges C. V., Adrenal cortical carcinoma. Journal of Urology 1978 120 6 660 665 2-s2.0-0018249921 (Pubitemid 9091388)
22. Fassnacht M., Johanssen S., Quinkler M., Bucsky P., Willenberg H. S., Beuschlein F., Terzolo M., Mueller H. H., Hahner S., Allolio B., Limited prognostic value of the 2004 international union against cancer staging classification for adrenocortical carcinoma. Cancer 2009 115 2 243 250 2-s2.0-59449084843 10.1002/cncr.24030
23. Lughezzani G., Sun M., Perrotte P., Jeldres C., Alasker A., Isbarn H., Budäus L., Shariat S. F., Guazzoni G., Montorsi F., Karakiewicz P. I., The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. European Journal of Cancer 2010 46 4 713 719 2-s2.0-76049095621 10.1016/j.ejca.2009.12.007
24. Icard P., Goudet P., Charpenay C., Andreassian B., Carnaille B., Chapuis Y., Cougard P., Henry J. F., Proye C., Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World Journal of Surgery 2001 25 7 891 897 2-s2.0-0034917097 10.1007/s00268-001-0047-y (Pubitemid 32666390)
25. Wooten M. D., King D. K., Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993 72 11 3145 3155 (Pubitemid 23356754)
26. Abiven G., Coste J., Groussin L., Anract P., Tissier F., Legmann P., Dousset B., Bertagna X., Bertherat J., Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. Journal of Clinical Endocrinology and Metabolism 2006 91 7 2650 2655 2-s2.0-33745777816 10.1210/jc.2005-2730 (Pubitemid 44024632)
27. Polat B., Fassnacht M., Pfreundner L., Guckenberger M., Bratengeier K., Johanssen S., Kenn W., Hahner S., Allolio B., Flentje M., Radiotherapy in adrenocortical carcinoma. Cancer 2009 115 13 2816 2823 2-s2.0-67649622025 10.1002/cncr.24331
28. Allolio B., Hahner S., Weismann D., Fassnacht M., Management of adrenocortical carcinoma. Clinical Endocrinology 2004 60 3 273 287 2-s2.0-1542329556 10.1046/j.1365-2265.2003.01881.x (Pubitemid 38297116)
29. Schteingart D. E., Doherty G. M., Gauger P. G., Giordano T. J., Hammer G. D., Korobkin M., Worden F. P., Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocrine-Related Cancer 2005 12 3 667 680 2-s2.0-17644399691 10.1677/erc.1.01029 (Pubitemid 41483000)
30. Berruti A., Terzolo M., Sperone P., Pia A., Della Casa S., Gross D. J., Carnaghi C., Casali P., Porpiglia F., Mantero F., Reimondo G., Angeli A., Dogliotti L., Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocrine-Related Cancer 2005 12 3 657 666 2-s2.0-26944468635 10.1677/erc.1.01025 (Pubitemid 41482999)
31. Abiven G., Coste J., Groussin L., Anract P., Tissier F., Legmann P., Dousset B., Bertagna X., Bertherat J., Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. Journal of Clinical Endocrinology and Metabolism 2006 91 7 2650 2655 2-s2.0-33745777816 10.1210/jc.2005-2730 (Pubitemid 44024632)
32. Giordano T. J., Thomas D. G., Kuick R., Lizyness M., Misek D. E., Smith A. L., Sanders D., Aljundi R. T., Gauger P. G., Thompson N. W., Taylor J. M. G., Hanash S. M., Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. American Journal of Pathology 2003 162 2 521 531 2-s2.0-0037331277 (Pubitemid 36267859)
33. Crucitti F., Bellantone R., Ferrante A., Boscherini M., Crucitti P., Carbone G., Casaccia M., Campisi C., Cavallaro A., Sapienza P., Del Gaudio A., Solidoro G., Dettori G., Marogna P., Di Giovanni V., Colli R., Doglietto G., Gozzetti G., Maldarizzi F., The italian registry for adrenal cortical carcinoma: analysis of a multiinstitutional series of 129 patients. Surgery 1996 119 2 161 170 2-s2.0-0029670955 10.1016/S0039-6060(96)80164-4 (Pubitemid 26052933)
34. Bergenstal D., Lipsett M., Moy R., Hertz R., Regression of adrenal cancer and suppression of adrenal function in men by o, p′-DDD. Transactions of American Physicians 1959 72 341
35. Luton J. P., Cerdas S., Billaud L., Thomas G., Guilhaume B., Bertagna X., Laudat M. H., Louvel A., Chapuis Y., Blondeau P., Bonnin A., Bricaire H., Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. The New England Journal of Medicine 1990 322 17 1195 1201 2-s2.0-0025248241 (Pubitemid 20137851)
36. Bukowski R. M., Wolfe M., Levine H. S., Crawford D. E., Stephens R. L., Gaynor E., Harker W. G., Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. Journal of Clinical Oncology 1993 11 1 161 165 2-s2.0-0027465121 (Pubitemid 23059990)
37. Khan T. S., Imam H., Juhlin C., Skogseid B., Gröndal S., Tibblin S., Wilander E., Öberg K., Eriksson B., Streptozocin and o,p′DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Annals of Oncology 2000 11 10 1281 1287 2-s2.0-0033767891 10.1023/A:1008377915129
38. Schteingart D. E., Conventional and novel strategies in the treatment of adrenocortical cancer. Brazilian Journal of Medical and Biological Research 2000 33 10 1197 1200 2-s2.0-0033784724
39. Hahner S., Fassnacht M., Mitotane for adrenocortical carcinoma treatment. Current Opinion in Investigational Drugs 2005 6 4 386 394 2-s2.0-17644420335 (Pubitemid 40561415)
40. Terzolo M., Angeli A., Fassnacht M., Daffara F., Tauchmanova L., Conton P. A., Rossetto R., Buci L., Sperone P., Grossrubatscher E., Reimondo G., Bollito E., Papotti M., Saeger W., Hahner S., Koschker A. C., Arvat E., Ambrosi B., Loli P., Lombardi G., Mannelli M., Bruzzi P., Mantero F., Allolio B., Dogliotti L., Berruti A., Adjuvant mitotane treatment for adrenocortical carcinoma. The New England Journal of Medicine 2007 356 23 2372 2380 2-s2.0-34249999500 10.1056/NEJMoa063360 (Pubitemid 46883771)
41. Williamson S. K., Lew D., Miller G. J., Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 2000 88 5 1159 1165 (Pubitemid 30127678)
42. Bonacci R., Gigliotti A., Baudin E., Wion-Barbot N., Emy P., Bonnay M., Cailleux A. F., Nakib I., Schlumberger M., Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. British Journal of Cancer 1998 78 4 546 549 2-s2.0-0031827589 (Pubitemid 28360647)
43. Burgess M. A., Legha S. S., Sellin R. V., Chemotherapy with cisplatinum and etoposide (UP16) for patients with advanced adrenal cortical carcinoma (ACC). Proceedings of the Annals of Society of Clinical Oncology 1993 12 188
44. Pommier R. F., Brennan M. F., An eleven-year experience with adrenocortical carcinoma. Surgery 1992 112 6 963 971 2-s2.0-0027051533 (Pubitemid 23008220)
45. Hedican S. P., Marshall F. F., Adrenocortical carcinoma with intracaval extension. Journal of Urology 1997 158 6 2056 2061 2-s2.0-0030779752 10.1016/S0022-5347(01)68152-7 (Pubitemid 27481326)
46. Schulick R. D., Brennan M. F., Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Annals of Surgical Oncology 1999 6 8 719 726 2-s2.0-0033396346 (Pubitemid 30013647)
47. Harrison L. E., Gaudin P. B., Brennan M. F., Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Archives of Surgery 1999 134 2 181 185 2-s2.0-0033028078 10.1001/archsurg.134.2. 181 (Pubitemid 29088971)
48. Gaujoux S., Bonnet S., Dousset B., Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. European Urology 2010 58 4 609 615 2-s2.0-78049474509 10.1016/j.eururo.2010.09. 001
49. Porpiglia F., Fiori C., Daffara F., Zaggia B., Bollito E., Volante M., Berruti A., Terzolo M., Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. European Urology 2010 57 5 873 878 2-s2.0-77949486954 10.1016/j.eururo.2010.01.036
50. Reibetanz J., Jurowich C., Erdogan I., Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Annals of Surgery 2012 25 2 363 369
51. Nelson A. A., Woodard G., Adrenal cortical atrophy and liver damage produced in dogs by feeding. Federation Proceedings 1948 7 1, part 1 277 2-s2.0-2442754291
52. Touitou Y., Bogdan A., Luton J. P., Changes in corticosteroid synthesis of the human adrenal cortex in vitro, induced by treatment with o,p′-DDD for Cushing's syndrome: evidence for the sites of action of the drug. Journal of Steroid Biochemistry 1978 9 12 1217 1224 2-s2.0-0018172226 (Pubitemid 9072393)
53. Bergenstal D. M., Hertz R., Lipsett M. B., Moy R. H., Chemotherapy of adrenocortical cancer with o, p′-DDD. Annals of Internal Medicine 1960 53 4 672 682
54. van Slooten H., Moolenaar A. J., van Seters A. P., Smeenk D., The treatment of adenocortical carcinoma with o,p'-DDD: prognostic simplications of serum level monitoring. European Journal of Cancer and Clinical Oncology 1984 20 1 47 53 2-s2.0-0021289017 (Pubitemid 14224356)
55. Hermsen I. G., Fassnacht M., Terzolo M., Houterman S., Den Hartigh J., Leboulleux S., Daffara F., Berruti A., Chadarevian R., Schlumberger M., Allolio B., Haak H. R., Baudin E., Plasma concentrations of o,p′DDD, o,p′DDA, and o,p′DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. Journal of Clinical Endocrinology and Metabolism 2011 96 6 1844 1851 2-s2.0-79956306619 10.1210/jc.2010-2676
56. van Erp N. P., Guchelaar H. J., Ploeger B. A., Romijn J. A., Den Hartigh J., Gelderblom H., Mitotane has a strong and a durable inducing effect on CYP3A4 activity. European Journal of Endocrinology 2011 164 4 621 626 2-s2.0-79953193793 10.1530/EJE-10-0956
57. Kirschner L. S., Emerging treatment strategies for adrenocortical carcinoma: a new hope. Journal of Clinical Endocrinology and Metabolism 2006 91 1 14 21 2-s2.0-30344471534 10.1210/jc.2005-1739 (Pubitemid 43069108)
58. Bates S. E., Shieh C. Y., Mickley L. A., Dichek H. L., Gazdar A., Loriaux D. L., Fojo A. T., Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. Journal of Clinical Endocrinology and Metabolism 1991 73 1 18 29 2-s2.0-0025739481 (Pubitemid 21901094)
59. Haak H. R., Hermans J., Van de Velde C. J. H., Lentjes E. G. W. M., Goslings B. M., Fleuren G. J., Krans H. M. J., Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. British Journal of Cancer 1994 69 5 947 951 2-s2.0-0028208020 (Pubitemid 24140681)
60. Bertherat J., Coste J., Bertagna X., Adjuvant mitotane in adrenocortical carcinoma. The New England Journal of Medicine 2007 357 12 1256 1257 2-s2.0-34548853467 10.1056/NEJMc076267
61. van Slooten H., van Seters A. P., Smeenk D., Moolenaar A. J., O,p′-DDD (mitotane) levels in plasma and tissues during chemotherapy and at autopsy. Cancer Chemotherapy and Pharmacology 1982 9 2 85 88 2-s2.0-0020376194 (Pubitemid 13243918)
62. Baudin E., Pellegriti G., Bonnay M., Impact of monitoring plasma 1,1 dichlorodiphenildichloroethane (o,p′DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001 92 6 1385 1392 (Pubitemid 32947821)
63. Phan A. T., Adrenal cortical carcinoma-review of current knowledge and treatment practices. Hematology/Oncology Clinics of North America 2007 21 3 489 507 2-s2.0-34249811195 10.1016/j.hoc.2007.04.007 (Pubitemid 46844860)
64. Wandoloski M., Bussey K. J., Demeure M. J., Adrenocortical Cancer. Surgical Clinics of North America 2009 89 5 1255 1267 2-s2.0-70349878953 10.1016/j.suc.2009.06.019
65. Lacroix A., Approach to the patient with adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2010 95 11 4812 4822 2-s2.0-78049511232 10.1210/jc.2010-0990
66. Kasperlik-Zaluska A. A., Migdalska B. M., Zgliczynski S., Makowska A. M., Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 1995 75 10 2587 2591
67. Wajchenberg B. L., Albergaria Pereira M. A., Medonca B. B., Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000 88 4 711 736 (Pubitemid 30091090)
68. Fassnacht M., Terzolo M., Allolio B., Combination chemotherapy in advanced adrenocortical carcinoma. The New England Journal of Medicine 2012 366 23 2189 2197
69. Libè R., Fratticci A., Bertherat J., Adrenocortical cancer: pathophysiology and clinical management. Endocrine-Related Cancer 2007 14 1 13 28 2-s2.0-34249810952 10.1677/erc.1.01130 (Pubitemid 47521719)
70. Sabolch A., Feng M., Griffith K., Hammer G., Doherty G., Ben-Josef E., Adjuvant and definitive radiotherapy for adrenocortical carcinoma. International Journal of Radiation Oncology Biology Physics 2011 80 5 1477 1484 2-s2.0-79960104319 10.1016/j.ijrobp.2010.04.030
71. Tacon L. J., Prichard R. S., Soon P. S. H., Robinson B. G., Clifton-Bligh R. J., Sidhu S. B., Current and emerging therapies for advanced adrenocortical carcinoma. Oncologist 2011 16 1 36 48 2-s2.0-79952604185 10.1634/theoncologist. 2010-0270
72. Fassnacht M., Hahner S., Polat B., Koschker A. C., Kenn W., Flentje M., Allolio B., Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2006 91 11 4501 4504 2-s2.0-33751529232 10.1210/jc.2006-1007 (Pubitemid 44833430)
73. Zini L., Porpiglia F., Fassnacht M., Contemporary management of adrenocortical carcinoma. European Urology 2011 60 5 1055 1065 2-s2.0-79961112038 10.1016/j.eururo.2011.07.062
74. Fassnacht M., Allolio B., What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? Clinical Endocrinology 2010 73 5 561 565 2-s2.0-78449291649 10.1111/j.1365-2265.2010.03867.x
75. Markoe A. M., Serber W., Micaily B., Brady L. W., Radiation therapy for adjunctive treatment of adrenal cortical carcinoma. American Journal of Clinical Oncology 1991 14 2 170 174 2-s2.0-0025778455
76. 2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines. Endocrine-Related Cancer 2008 15 2 623 634 2-s2.0-45849101318 10.1677/erc.1.1315 (Pubitemid 351880848)
77. 2 arrest and mismatch repair enzymes modulation. International Journal of Oncology 2010 37 2 493 501 2-s2.0-77954150536 10.3892/ijo-0000698
78. Hermsen I. G. C., Groenen Y. E., Dercksen M. W., Theuws J., Haak H. R., Response to radiation therapy in adrenocortical carcinoma. Journal of Endocrinological Investigation 2010 33 10 712 714 2-s2.0-79951667879 10.3275/6904
79. Maluf D. F., de Oliveira B. H., Lalli E., Therapy of adrenocortical cancer: present and future. American Journal of Cancer Research 2011 1 2 222 232
80. Latronico A. C., Pinto E. M., Domenice S., Barisson Villares Fragoso M. C., Martin R. M., Zerbini M. C., Lucon A. M., Mendonca B. B., An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 2001 86 10 4970 4973 2-s2.0-0034750121 10.1210/jc.86.10.4970 (Pubitemid 33020551)
81. Barlaskar F. M., Hammer G. D., The molecular genetics of adrenocortical carcinoma. Reviews in Endocrine and Metabolic Disorders 2007 8 4 343 348 2-s2.0-38049050719 10.1007/s11154-007-9057-x
82. de Reyniès A., Assié G., Rickman D. S., Tissier F., Groussin L., René-Corail F., Dousset B., Bertagna X., Clauser E., Bertherat J., Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. Journal of Clinical Oncology 2009 27 7 1108 1115 2-s2.0-61449137784 10.1200/JCO.2008.18.5678
83. Barlaskar F. M., Spalding A. C., Heaton J. H., Kuick R., Kim A. C., Thomas D. G., Giordano T. J., Ben-Josef E., Hammer G. D., Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2009 94 1 204 212 2-s2.0-58149381997 10.1210/jc.2008-1456
84. Ragazzon B., Assié G., Bertherat J., Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments. Endocrine-Related Cancer 2011 18 2 R15 R27 2-s2.0-79953165342 10.1530/ERC-10-0220
85. Carden C. P., Frentzas S., Langham M., Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors. Journal of Clinical Oncology 2009 27 15 3544
86. Haluska P., Worden F., Olmos D., Yin D., Schteingart D., Batzel G. N., Paccagnella M. L., De Bono J. S., Gualberto A., Hammer G. D., Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemotherapy and Pharmacology 2010 65 4 765 773 2-s2.0-75749102231 10.1007/s00280-009-1083-9
87. Giordano T. J., Adrenocortical tumors an integrated clinical, pathologic, and molecular approach at the university of Michigan. Archives of Pathology and Laboratory Medicine 2010 134 10 1440 1443 2-s2.0-77958588047
88. Doghman M., El Wakil A., Cardinaud B., Thomas E., Wang J., Zhao W., Peralta-Del Valle M. H. C., Figueiredo B. C., Zambetti G. P., Lalli E., Regulation of IGFmTOR signalling by miRNA in childhood adrenocortical tumors. Cancer Research 2010 70 11 4666 4675 2-s2.0-77953168294 10.1158/0008-5472.CAN- 09-3970
89. De Martino M. C., van Koetsveld P. M., Pivonello R., Hofland L. J., Role of the mTOR pathway in normal and tumoral adrenal cells. Neuroendocrinology 2010 92 1 28 34 2-s2.0-77956533046 10.1159/000314280
90. Naing A., Kurzrock R., Burger A., Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clinical Cancer Research 2011 17 18 6052 6060
91. Wortmann S., Quinkler M., Ritter C., Kroiss M., Johanssen S., Hahner S., Allolio B., Fassnacht M., Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. European Journal of Endocrinology 2010 162 2 349 356 2-s2.0-75149143015 10.1530/EJE-09-0804
92. Chacón R., Tossen G., Loria F. S., Chacón M., CASE 2. Response in a patient with metastatic adrenal cortical carcinoma with thalidomide. Journal of Clinical Oncology 2005 23 7 1579 1580 2-s2.0-14944378110 10.1200/JCO.2005.03.195
93. Fassnacht M., Kreissl M. C., Weismann D., Allolio B., New targets and therapeutic approaches for endocrine malignancies. Pharmacology and Therapeutics 2009 123 1 117 141 2-s2.0-65749120532 10.1016/j.pharmthera.2009.03.013
94. Lee J. O., Lee K. W., Kim C. J., Kim Y. J., Lee H. E., Kim H., Kim J. H., Bang S. M., Kim J. S., Lee J. S., Metastatic adrenocortical carcinoma treated with sunitinib: a case report. Japanese Journal of Clinical Oncology 2009 39 3 183 185 2-s2.0-61449181257 10.1093/jjco/hyn146
95. Hong D. S., Sebti S. M., Newman R. A., Blaskovich M. A., Ye L., Gagel R. F., Moulder S., Wheler J. J., Naing A., Tannir N. M., Ng C. S., Sherman S. I., El Naggar A. K., Khan R., Trent J., Wright J. J., Kurzrock R., Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clinical Cancer Research 2009 15 22 7061 7068 2-s2.0-72549092909 10.1158/1078-0432.CCR-09-1241
96. Butler C., Butler W. M., Rizvi A. A., Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma. Endocrine Practice 2010 16 3 441 445 2-s2.0-77956634862 10.4158/EP09295.CR
97. Berruti A., Sperone P., Ferrero A., Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. European Journal of Endocrinology 2012 166 3 451 458
98. Gangadhar T. C., Cohen E. E. W., Wu K., Janisch L., Geary D., Kocherginsky M., House L. K., Ramirez J., Undevia S. D., Maitland M. L., Fleming G. F., Ratain M. J., Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clinical Cancer Research 2011 17 7 1956 1963 2-s2.0-79953307456 10.1158/1078-0432.CCR-10- 2061
99. Xu Y. Z., Zhu Y., Shen Z. J., Sheng J. Y., He H. C., Ma G., Qi Y. C., Zhao J. P., Wu Y. X., Rui W. B., Wei Q., Zhou W. L., Xie X., Ning G., Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy. Endocrine 2011 40 3 445 451 2-s2.0-79959426442 10.1007/s12020-011-9502-1
100. Assié G., Guillaud-Bataille M., Ragazzon B., Bertagna X., Bertherat J., Clauser E., The pathophysiology, diagnosis and prognosis of adrenocortical tumors revisited by transcriptome analyses. Trends in Endocrinology and Metabolism 2010 21 5 325 334 2-s2.0-77952510754 10.1016/j.tem.2009.12.009
101. Dorfinger K., Vierhapper H., Wilfing A., Czernin S., Niederle B., Nowotny P., Peterlik M., Waldhausl W., Grubeck-Loebenstein B., The effects of suramin on human adrenocortical cells in vitro: suramin inhibits cortisol secretion and adrenocortical cell growth. Metabolism 1991 40 10 1020 1024 2-s2.0-0025938547 10.1016/0026-0495(91)90123-E
102. Arlt W., Reincke M., Siekmann L., Winkelmann W., Allolio B., Suramin in adrenocortical cancer: limited efficacy and serious toxicity. Clinical Endocrinology 1994 41 3 299 307 2-s2.0-0028075055 (Pubitemid 24278323)
103. Quinkler M., Hahner S., Wortmann S., Johanssen S., Adam P., Ritte C., Strasburger C., Allolio B., Fassnacht M., Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. Journal of Clinical Endocrinology and Metabolism 2008 93 6 2057 2062 2-s2.0-45149110737 10.1210/jc.2007-2564 (Pubitemid 351831515)
104. Samnotra V., Vassilopoulou-Sellin R., Fojo A. T., A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). Journal of Clinical Oncology 2007 27 18 15527
105. Adam P., Hahner S., Hartmann M., Heinrich B., Quinkler M., Willenberg H. S., Saeger W., Sbiera S., Schmull S., Voelker H. U., Ströbel P., Allolio B., Fassnacht M., Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Modern Pathology 2010 23 12 1596 1604 2-s2.0-78649705561 10.1038/modpathol.2010.153
106. Gross D. J., Munter G., Bitan M., Siegal T., Gabizon A., Weitzen R., Merimsky O., Ackerstein A., Salmon A., Sella A., Slavin S., The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocrine-Related Cancer 2006 13 2 535 540 2-s2.0-33745067446 10.1677/erc.1.01124 (Pubitemid 43886675)
107. Ronchi C. L., Sbiera S., Kraus L., Wortmann S., Johanssen S., Adam P., Willenberg H. S., Hahner S., Allolio B., Fassnacht M., Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocrine-Related Cancer 2009 16 3 907 918 2-s2.0-72749100910 10.1677/ERC-08-0224
108. Takara K., Sakaeda T., Okumura K., An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Current Pharmaceutical Design 2006 12 3 273 286 2-s2.0-33644860579 10.2174/138161206775201965
109. Fridborg H., Larsson R., Juhlin C., Rastad J., Akerstrom G., Baklin K., Nygren P., P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells. Anticancer Research 1994 14 3 A 1009 1016 2-s2.0-0027955902 (Pubitemid 24272559)
110. Feller N., Hoekman K., Kuiper C. M., Linn S. C., Verheul H. M. W., Wolthers B. G., Popp-Snijders C., Pinedo H. M., A patient with adrenocortical carcinoma: characterization of its biological activity and drug resistance profile. Clinical Cancer Research 1997 3 3 389 394 2-s2.0-0030887352 (Pubitemid 27158062)
111. Abraham J., Bakke S., Rutt A., Meadows B., Merino M., Alexander R., Schrump D., Bartlett D., Choyke P., Robey R., Hung E., Steinberg S. M., Bates S., Fojo T., A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 2002 94 9 2333 2343 2-s2.0-0036569569 10.1002/cncr.10487 (Pubitemid 34457113)
112. Betz M. J., Shapiro I., Fassnacht M., Hahner S., Reincke M., Beuschlein F., Peroxisome proliferator-activated receptor- γ agonists suppress adrenocortical tumor cell proliferation and induce differentiation. Journal of Clinical Endocrinology and Metabolism 2005 90 7 3886 3896 2-s2.0-23044448369 10.1210/jc.2004-1267 (Pubitemid 41058147)
113. Ferruzzi P., Ceni E., Tarocchi M., Grappone C., Milani S., Galli A., Fiorelli G., Serio M., Mannelli M., Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. Journal of Clinical Endocrinology and Metabolism 2005 90 3 1332 1339 2-s2.0-15944416421 10.1210/jc.2004-0978 (Pubitemid 40463984)
114. Cantini G., Lombardi A., Piscitelli E., Poli G., Elisabetta C., Sara M., Tonino E., Andrea G., Mario S., Massimo M., Michaela L., Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling. PPAR Research 2008 2008 11 2-s2.0-49749113948 10.1155/2008/904041 904041
115. Luconi M., Mangoni M., Gelmini S., Poli G., Nesi G., Francalanci M., Pratesi N., Cantini G., Lombardi A., Pepi M., Ercolino T., Serio M., Orlando C., Mannelli M., Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model. Endocrine-Related Cancer 2010 17 1 169 177 2-s2.0-77449098099 10.1677/ERC-09-0170
116. Cerquetti L., Sampaoli C., Amendola D., Bucci B., Masuelli L., Marchese R., Misiti S., De Venanzi A., Poggi M., Toscano V., Stigliano A., Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells. Experimental Cell Research 2011 317 10 1397 1410 2-s2.0-79955949199 10.1016/j.yexcr.2011.02.014
117. Kim A. C., Barlaskar F. M., Heaton J. H., Else T., Kelly V. R., Krill K. T., Scheys J. O., Simon D. P., Trovato A., Yang W. H., Hammer G. D., In search of adrenocortical stem and progenitor cells. Endocrine Reviews 2009 30 3 241 263 2-s2.0-65649085632 10.1210/er.2008-0039
118. Gaujoux S., Grabar S., Fassnacht M., Ragazzon B., Launay P., Libé R., Chokri I., Audebourg A., Royer B., Sbiera S., Vacher-Lavenu M. C., Dousset B., Bertagna X., Allolio B., Bertherat J., Tissier F., β -catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clinical Cancer Research 2011 17 2 328 336 2-s2.0-79251475279 10.1158/1078-0432.CCR-10-2006
119. Doghman M., Cazareth J., Lalli E., The T cell factor/ β -catenin
120. Demeure M. J., Bussey K. J., Kirschner L. S., Targeted therapies for adrenocortical carcinoma: IGF and beyond. Hormone Cancer 2011 2 6 385 392
121. Garber K., Drugging the Wnt pathway: problems and progress. Journal of the National Cancer Institute 2009 101 8 548 550 2-s2.0-64749113970 10.1093/jnci/djp084
122. Almeida M. Q., Soares I. C., Ribeiro T. C., Fragoso M. C. B. V., Marins L. V., Wakamatsu A., Ressio R. A., Nishi M. Y., Jorge A. A. L., Lerario A. M., Alves V. A. F., Mendonca B. B., Latronico A. C., Steroidogenic factor 1 overexpression and gene amplification are more frequent in adrenocortical tumors from children than from adults. Journal of Clinical Endocrinology and Metabolism 2010 95 3 1458 1462 2-s2.0-77749233736 10.1210/jc.2009-2040
123. Sbiera S., Schmull S., Assie G., Voelker H. U., Kraus L., Beyer M., Ragazzon B., Beuschlein F., Willenberg H. S., Hahner S., Saeger W., Bertherat J., Allolio B., Fassnacht M., High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. Journal of Clinical Endocrinology and Metabolism 2010 95 10 E161 E171 2-s2.0-77957771843 10.1210/jc.2010-0653
124. Doghman M., Karpova T., Rodrigues G. A., Arhatte M., De Moura J., Cavalli L. R., Virolle V., Barbry P., Zambetti G. P., Figueiredo B. C., Heckert L. L., Lalli E., Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Molecular Endocrinology 2007 21 12 2968 2987 2-s2.0-36849073202 10.1210/me.2007-0120 (Pubitemid 350223508)
125. Ehrlund A., Jonsson P., Vedin L. L., Knockdown of SF-1 and RNF31 affects components of steroidogenesis, TGFâ and Wnt/â-catenin signaling in adrenocortical carcinoma cells. PLoS One 2012 7 3 e32080
126. Doghman M., Cazareth J., Douguet D., Madoux F., Hodder P., Lalli E., Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists. Journal of Clinical Endocrinology and Metabolism 2009 94 6 2178 2183 2-s2.0-66749179396 10.1210/jc.2008-2163
127. Chuman Y., Zhan Z., Fojo T., Construction of gene therapy vectors targeting adrenocortical cells: Enhancement of activity and specificity with agents modulating the cyclic adenosine 3′5′-monophosphate pathway. Journal of Clinical Endocrinology and Metabolism 2000 85 1 253 262 2-s2.0-0034457809 10.1210/jc.85.1.253 (Pubitemid 32268823)
128. Sbiera S., Wortmann S., Fassnacht M., Dendritic cell based immunotherapya promising therapeutic approach for endocrine malignancies. Hormone and Metabolic Research 2008 40 2 89 98 2-s2.0-40549126990 10.1055/s-2007-1022549 (Pubitemid 351363419)
129. Papewalis C., Fassnacht M., Willenberg H. S., Domberg J., Fenk R., Rohr U. P., Schinner S., Bornstein S. R., Scherbaum W. A., Schott M., Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma. Clinical Endocrinology 2006 65 2 215 222 2-s2.0-33746036541 10.1111/j.1365-2265.2006. 02576.x (Pubitemid 44079686)
130. Ortmann D., Hausmann J., Beuschlein F., Schmenger K., Stahl M., Geissler M., Reincke M., Steroidogenic acute regulatory (StaR)-directed immunotherapy protects against tumor growth of StaR-expressing Sp2-0 cells in a rodent adrenocortical carcinoma model. Endocrinology 2004 145 4 1760 1766 2-s2.0-1642505640 10.1210/en.2003-0983 (Pubitemid 38402384)
131. Barzon L., Masi G., Pacenti M., Trevisan M., Fallo F., Remo A., Martignoni G., Montanaro D., Pezzi V., Palù G., Expression of aromatase and estrogen receptors in human adrenocortical tumors. Virchows Archiv 2008 452 2 181 191 2-s2.0-39149134907 10.1007/s00428-007-0542-0
132. Matthews J., Gustafsson J. A., Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv 2003 3 5 281 292 2-s2.0-1642332240
133. de Cremoux P., Rosenberg D., Goussard J., Brémont-Weil C., Tissier F., Tran-Perennou C., Groussin L., Bertagna X., Bertherat J., Raffin-Sanson M. L., Expression of progesterone and estradiol receptors in normal adrenal cortex, adrenocortical tumors, and primary pigmented nodular adrenocortical disease. Endocrine-Related Cancer 2008 15 2 465 474 2-s2.0-45849125066 10.1677/ERC-07-0081 (Pubitemid 351880835)
134. Montanaro D., Maggiolini M., Recchia A. G., Sirianni R., Aquila S., Barzon L., Fallo F., Andò S., Pezzi V., Antiestrogens upregulate estrogen receptor β expression and inhibit adrenocortical H295R cell proliferation. Journal of Molecular Endocrinology 2005 35 2 245 256 2-s2.0-27644504201 10.1677/jme.1.01806 (Pubitemid 41556173)
135. Sirianni R., Zolea F., Chimento A., Targeting estrogen receptor á reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of Selective Estrogen Receptor modulators (SERMs) for ACC treatment. submitted to Journal Clinical Endocrinology and Metabolism